A. Craiu et al., An IL-2/Ig fusion protein influences CD4(+) T lymphocytes in naive and simian immunodeficiency virus-infected rhesus monkeys, AIDS RES H, 17(10), 2001, pp. 873-886
The T cell-stimulatory cytokine interleukin 2 (IL-2) is being evaluated as
a therapeutic in the clinical settings of HIV infection and cancer. However
, the clinical utility of IL-2 may be mitigated by its short in vivo half-l
ife, toxic effects, and high production costs. We show here that an IL-2/Ig
fusion protein possesses IL-2 immunostimulatory activity in vitro and a lo
ng in vivo half-life. IL-2/Ig treatment of healthy rhesus monkeys induced s
ignificant increases in CD4(+) T lymphocyte counts and expression of CD25 b
y these cells. Short courses of IL-2/Ig treatment of simian immunodeficienc
y virus (SIV)-infected rhesus monkeys in conjunction with antiretroviral dr
ugs resulted in increased CD25 expression on T lymphocytes, and transient i
ncreases in CD4(+) T lymphocyte counts. Plasma viremia did not increase in
these treated animals. Treatment of healthy or SIV-infected rhesus monkeys
with a plasmid encoding the IL-2/Ig protein did not affect CD4(+) T lymphoc
ytes. These results demonstrate that IL-2/Ig has potential utility as an im
munostimulatory therapeutic.